{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T21:23:53Z","timestamp":1786224233546,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s40265-015-0484-9","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T08:29:17Z","timestamp":1446712157000},"page":"2017-2024","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"key":"484_CR1","unstructured":"World Health Organization. Cancer: fact sheet no. 297. 2015. http:\/\/www.who.int . Accessed 5 Oct 2015."},{"key":"484_CR2","doi-asserted-by":"crossref","unstructured":"Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27\u201339.","DOI":"10.1093\/annonc\/mdu199"},{"issue":"10","key":"484_CR3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.6004\/jnccn.2012.0130","volume":"10","author":"DS Ettinger","year":"2012","unstructured":"Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012;10(10):1236\u201371.","journal-title":"J Natl Compr Canc Netw."},{"key":"484_CR4","doi-asserted-by":"crossref","unstructured":"Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475\u201384.","DOI":"10.1093\/annonc\/mdu123"},{"issue":"7","key":"484_CR5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003495-200666070-00007","volume":"66","author":"DM Robinson","year":"2006","unstructured":"Robinson DM, Keating GM. Albumin-bound paclitaxel: in metastatic breast cancer. Drugs. 2006;66(7):941\u20138.","journal-title":"Drugs."},{"issue":"13","key":"484_CR6","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590\u20138.","journal-title":"Eur J Cancer."},{"issue":"4","key":"484_CR7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317\u201324.","journal-title":"Clin Cancer Res."},{"key":"484_CR8","unstructured":"Celgene Corporation. Abraxane\u00ae for injectable suspension (paclitaxel protein-bound particles for injectable suspension) [albumin-bound]: US prescribing information. 2014. http:\/\/www.fda.gov\/ . Accessed 5 Oct 2015."},{"key":"484_CR9","unstructured":"European Medicines Agency. Abraxane 5 mg\/ml powder for suspension for infusion: summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 5 Oct 2015."},{"issue":"5","key":"484_CR10","first-page":"1038","volume":"8","author":"NK Ibrahim","year":"2002","unstructured":"Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8(5):1038\u201344.","journal-title":"Clin Cancer Res."},{"issue":"13","key":"484_CR11","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14(13):4200\u20135.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"484_CR12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jjco\/hyp192","volume":"40","author":"K Yamada","year":"2010","unstructured":"Yamada K, Yamamoto N, Yamada Y, et al. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol. 2010;40(5):404\u201311.","journal-title":"Jpn J Clin Oncol."},{"issue":"5","key":"484_CR13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-007-0423-x","volume":"60","author":"TE Stinchcombe","year":"2007","unstructured":"Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol. 2007;60(5):759\u201366.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"484_CR14","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s10637-011-9674-9","volume":"30","author":"I Okamoto","year":"2012","unstructured":"Okamoto I, Yamamoto N, Kubota K, et al. Safety and pharmacokinetic study of nab -paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer. Invest New Drugs. 2012;30(3):1132\u20137.","journal-title":"Invest New Drugs."},{"key":"484_CR15","doi-asserted-by":"crossref","unstructured":"Bertino EM, Williams TM, Shilo K, et al. Phase 2 trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies [abstract no. 193]. Int J Radiat Oncol Biol Phys. 2014;90(5 Suppl 1):S45.","DOI":"10.1016\/j.ijrobp.2014.08.232"},{"issue":"17","key":"484_CR16","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.7314\/APJCP.2014.15.17.7453","volume":"15","author":"Y Fang","year":"2014","unstructured":"Fang Y, Wang L, Xia GH, et al. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III\/IV squamous non-small cell lung cancer. Asian Pac J Cancer Prev. 2014;15(17):7453\u20137.","journal-title":"Asian Pac J Cancer Prev."},{"issue":"8","key":"484_CR17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","volume":"17","author":"MR Green","year":"2006","unstructured":"Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8):1263\u20138.","journal-title":"Ann Oncol."},{"issue":"Suppl 2","key":"484_CR18","first-page":"S566","volume":"8","author":"L Lin","year":"2013","unstructured":"Lin L, Chen H, Huang X, et al. Nab-paclitaxel (Abraxane) based chemotherapy for pretreated elderly advanced NSCLC patients: an open-label, single center, randomized phase II trial [abstract no. P1.10-013]. J Thorac Oncol. 2013;8(Suppl 2):S566\u20137.","journal-title":"J Thorac Oncol."},{"issue":"5","key":"484_CR19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00280-011-1621-0","volume":"68","author":"PK Paik","year":"2011","unstructured":"Paik PK, James LP, Riely GJ, et al. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane) given as a two-hour infusion. Cancer Chemother Pharmacol. 2011;68(5):1331\u20137.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"12","key":"484_CR20","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/JTO.0b013e3181c0a2f4","volume":"4","author":"C Reynolds","year":"2009","unstructured":"Reynolds C, Barrera D, Jotte R, et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1537\u201343.","journal-title":"J Thorac Oncol."},{"issue":"6","key":"484_CR21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/JTO.0b013e3181d5e39e","volume":"5","author":"MA Socinski","year":"2010","unstructured":"Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(6):852\u201361.","journal-title":"J Thorac Oncol."},{"key":"484_CR22","doi-asserted-by":"crossref","unstructured":"Yang J, Huang C, Song Y, et al. A phase II trial of first-line nab-paclitaxel\/carboplatin versus gemcitabine\/carboplatin in advanced squamous cell carcinoma of the lung (CTONG1002) [abstract no. 8085]. J Clin Oncol. 2014;32(15 Suppl 1).","DOI":"10.1200\/jco.2014.32.15_suppl.8085"},{"issue":"4","key":"484_CR23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10555-008-9146-7","volume":"27","author":"OL Podhajcer","year":"2008","unstructured":"Podhajcer OL, Benedetti LG, Girotti MR, et al. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008;27(4):691\u2013705.","journal-title":"Cancer Metastasis Rev."},{"issue":"11","key":"484_CR24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5732\/cjc.011.10377","volume":"31","author":"Y Huang","year":"2012","unstructured":"Huang Y, Zhang J, Zhao YY, et al. SPARC expression and prognostic value in non-small cell lung cancer. Chin J Cancer. 2012;31(11):541\u20138.","journal-title":"Chin J Cancer."},{"key":"484_CR25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fphys.2014.00299","volume":"5","author":"AM Merlot","year":"2014","unstructured":"Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 2014;5:299.","journal-title":"Front Physiol."},{"issue":"6","key":"484_CR26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/JTO.0b013e318217b739","volume":"6","author":"H Shao","year":"2011","unstructured":"Shao H, Tang H, Salavaggione OE, et al. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol. 2011;6(6):998\u20131005.","journal-title":"J Thorac Oncol."},{"issue":"1","key":"484_CR27","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/1471-2407-14-684","volume":"14","author":"JJ Yang","year":"2014","unstructured":"Yang JJ, Huang C, Chen GY, et al. A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung. BMC Cancer. 2014;14(1):684.","journal-title":"BMC Cancer."},{"issue":"2","key":"484_CR28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-011-1726-5","volume":"69","author":"M Ando","year":"2012","unstructured":"Ando M, Yonemori K, Katsumata N, et al. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol. 2012;69(2):457\u201365.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"11","key":"484_CR29","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","volume":"11","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res. 2005;11(11):4136\u201343.","journal-title":"Clin Cancer Res."},{"issue":"10","key":"484_CR30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jcph.304","volume":"54","author":"N Chen","year":"2014","unstructured":"Chen N, Li Y, Ye Y, et al. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014;54(10):1097\u2013107.","journal-title":"J Clin Pharmacol."},{"issue":"17","key":"484_CR31","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055\u201362.","journal-title":"J Clin Oncol."},{"key":"484_CR32","doi-asserted-by":"crossref","unstructured":"Hirsh V, Owen SP, Ko A, et al. Analysis of outcomes in diabetic patients in a phase 3 trial of nab-paclitaxel (nab-P) plus carboplatin (C) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) [abstract no. 137]. Int J Radiat Oncol Biol Phys. 2014;90(5 Suppl 1):S21.","DOI":"10.1016\/j.ijrobp.2014.08.176"},{"key":"484_CR33","doi-asserted-by":"crossref","unstructured":"Hirsh V, Page RD, Ko A, et al. Analysis of predictive factors in a phase 3 trial of nab-paclitaxel (nab-P) plus carboplatin (C) as first-line therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract no. 189]. Int J Radiat Oncol Biol Phys. 2014;90(5 Suppl 2):S43.","DOI":"10.1016\/j.ijrobp.2014.08.228"},{"key":"484_CR34","doi-asserted-by":"crossref","unstructured":"Langer CJ, Hirsh V, Wan Y, et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing nab-paclitaxel plus carboplatin (nab-PC) with solvent-based paclitaxel plus carboplatin (sb-PC) in first-line advanced non-small cell lung cancer (NSCLC) [abstract no. e19004]. J Clin Oncol. 2014;32(15 Suppl 1).","DOI":"10.1200\/jco.2014.32.15_suppl.e19004"},{"issue":"Suppl 4","key":"484_CR35","first-page":"S242","volume":"9","author":"M Socinski","year":"2012","unstructured":"Socinski M, Okamoto I, Hon JK, et al. Nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): analysis of pt characteristics and clinical treatment patterns by region [abstract no. 183]. J Thorac Oncol. 2012;9(Suppl 4):S242\u20133.","journal-title":"J Thorac Oncol."},{"issue":"Suppl 2","key":"484_CR36","first-page":"S404","volume":"8","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, Ko A, Renschler MF. Nab-paclitaxel plus carboplatin in patients (pts) with squamous cell (SCC) non-small cell lung cancer (NSCLC): analysis of pts treated beyond 4 cycles in a pivotal phase 3 trial [abstract no. MO24.07]. J Thorac Oncol. 2013;8(Suppl 2):S404.","journal-title":"J Thorac Oncol."},{"issue":"9","key":"484_CR37","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/annonc\/mdt235","volume":"24","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, Okamoto I, Hon JK, et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(9):2390\u20136.","journal-title":"Ann Oncol."},{"issue":"2","key":"484_CR38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/annonc\/mds461","volume":"24","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, Langer CJ, Okamoto I, et al. Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(2):314\u201321.","journal-title":"Ann Oncol."},{"issue":"1","key":"484_CR39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2013.02.020","volume":"81","author":"M Satouchi","year":"2013","unstructured":"Satouchi M, Okamoto I, Sakai H, et al. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2013;81(1):97\u2013101.","journal-title":"Lung Cancer."},{"issue":"2","key":"484_CR40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cllc.2014.09.003","volume":"16","author":"CJ Langer","year":"2015","unstructured":"Langer CJ, Hirsh V, Ko A, et al. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Clin Lung Cancer. 2015;16(2):112\u201320.","journal-title":"Clin Lung Cancer."},{"issue":"1","key":"484_CR41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bjc.2015.181","volume":"113","author":"CJ Langer","year":"2015","unstructured":"Langer CJ, Hirsh V, Okamoto I, et al. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Br J Cancer. 2015;113(1):20\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"484_CR42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/JTO.0000000000000011","volume":"9","author":"V Hirsh","year":"2014","unstructured":"Hirsh V, Okamoto I, Hon JK, et al. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(1):83\u201390.","journal-title":"J Thorac Oncol."},{"issue":"Suppl 2","key":"484_CR43","first-page":"S569","volume":"8","author":"H Sakai","year":"2013","unstructured":"Sakai H, Ko A, Renschler MF, et al. Nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC): analysis of peripheral neuropathy [abstract no. P1.10-018]. J Thorac Oncol. 2013;8(Suppl 2):S569\u201370.","journal-title":"J Thorac Oncol."},{"key":"484_CR44","first-page":"209","volume":"9","author":"N Gupta","year":"2014","unstructured":"Gupta N, Hatoum H, Dy GK. First line treatment of advanced non-small-cell lung cancer\u2014specific focus on albumin bound paclitaxel. Int J Nanomed. 2014;9:209\u201321.","journal-title":"Int J Nanomed"},{"issue":"5","key":"484_CR45","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.3747\/co.21.1997","volume":"21","author":"MA Socinski","year":"2014","unstructured":"Socinski MA. Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. Curr Oncol. 2014;21(5):e691\u2013703.","journal-title":"Curr Oncol."},{"issue":"17","key":"484_CR46","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1200\/JCO.2011.41.4912","volume":"30","author":"MN Levine","year":"2012","unstructured":"Levine MN, Juergens R. Method to our madness or madness in our methods? Pitfalls in trial methodology. J Clin Oncol. 2012;30(17):2025\u20136.","journal-title":"J Clin Oncol."},{"key":"484_CR47","doi-asserted-by":"crossref","unstructured":"Spigel DR, Ko A, Ong TJ, et al. ABOUND.sqm: a phase 3 randomized study of maintenance nab-paclitaxel (NAB-P) after induction therapy with NAB-P plus carboplatin (C) in patients (pts) with squamous cell (SCC) non-small cell lung cancer (NSCLC) [abstract no. 1221TiP]. Ann Oncol. 2014;25:iv417\u2013iv425.","DOI":"10.1093\/annonc\/mdu348.26"},{"key":"484_CR48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1472-6963-11-305","volume":"11","author":"M Vera-Llonch","year":"2011","unstructured":"Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. BMC Health Serv Res. 2011;11:305.","journal-title":"BMC Health Serv Res."},{"issue":"Suppl 2","key":"484_CR49","first-page":"S1176","volume":"8","author":"D Spigel","year":"2013","unstructured":"Spigel D, Harwin W, Dranitsaris G, et al. Nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): an economic analysis [abstract no. P3.10-043]. J Thorac Oncol. 2013;8(Suppl 2):S1176\u20137.","journal-title":"J Thorac Oncol."},{"key":"484_CR50","doi-asserted-by":"crossref","unstructured":"Hirsh V, Berger A, Binder G, et al. Cost effectiveness of nab-paclitaxel plus carboplatin (nab-PC) relative to bevacizumab plus solvent-based paclitaxel and carboplatin (B+sb-PC) in elderly patients with advanced non-small cell lung cancer (NSCLC) [abstract no. 238]. Int J Radiat Oncol Biol Phys. 2014;90(5 Suppl 1):S61\u2013S2.","DOI":"10.1016\/j.ijrobp.2014.08.278"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0484-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0484-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T08:25:52Z","timestamp":1567326352000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0484-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":50,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0484-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}